| Popis: |
Pietro Di Marino,1 Gianluca Mannetta,2 Consiglia Carella,3 Antonino Grassadonia,3 Nicola Tinari,3 Clara Natoli,3 Michele De Tursi3 1Clinical Oncology Unit, S.S. Annunziata Hospital, Chieti, Italy; 2Department of Neuroscience, Imaging and Clinical Sciences, “G. d’Annunzio” University, Chieti, Italy; 3Department of Medical, Oral and Biotechnological Sciences University “G. D’Annunzio”, Chieti-Pescara, ItalyCorrespondence: Pietro Di MarinoClinical Oncology Unit, PO SS Annunziata, Via Dei Vestini 5, Chieti 66100, ItalyTel +39 871 35 8005Fax +39 871 35 8476Email pietrodimarino@gmail.comBackground: Crizotinib is the first tyrosine kinase inhibitor approved for the treatment of anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer (NSCLC). An increased incidence of renal cysts has been described during the crizotinib treatment.Case Presentation: We herein report the case of a 74-year-old woman who received crizotinib for metastatic ALK-positive NSCLC. During the crizotinib treatment, complex renal cystic lesions with invasion of perirenal spaces and iliopsoas muscle appeared; two complex hepatic cysts were also observed. Almost all lesions disappeared after switching to alectinib, a second-generation ALK inhibitor.Conclusion: It would seem that alectinib is able to reduce in size and number hepatic and renal cysts caused by the crizotinib treatment. Nevertheless, further studies are needed to clarify the role of both crizotinib in the onset of renal and hepatic cysts and alectinib in their disappearance.Keywords: anaplastic lymphoma kinase, crizotinib, alectinib, non-small-cell lung cancer, renal cysts, hepatic cysts |
